Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Drug

3D Medicines Secures Registration for Envafolimab in Macau for Advanced Solid Tumors

Fineline Cube Jan 16, 2024

3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1...

Company Drug

Hope Medicine Initiates Phase II Trial for HMI-115 in Endometriosis Treatment

Fineline Cube Jan 16, 2024

Hope Medicine Inc., based in China, has announced the first patient dosing in a global...

Company Drug

Neuboron Medtech Secures Clinical Trial Approval for First BNCT Drug in China

Fineline Cube Jan 16, 2024

Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b)...

Company

AstraZeneca China Announces Leadership Changes and New Biopharmaceutical Unit

Fineline Cube Jan 16, 2024

AstraZeneca (AZ, NASDAQ: AZN)’s China unit is set to undergo significant organizational changes, including the...

Company Drug

SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer

Fineline Cube Jan 16, 2024

SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...

Policy / Regulatory

China’s State Council Unveils 26 Initiatives to Enhance Grey-hair Economy

Fineline Cube Jan 16, 2024

The State Council has unveiled the “Opinions on Developing the Grey-hair Economy to Boost Wellbeing...

Company Deals

China Grand Pharma to Acquire 63% Stake in Duoputai for RMB 442 Million

Fineline Cube Jan 16, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced its intention to...

Company Drug

Bayer’s Asklepios BioPharmaceutical Launches Phase II Trial for AAV Therapy in Heart Failure

Fineline Cube Jan 16, 2024

Bayer’s (ETR: BAYN) gene therapy subsidiary, Asklepios BioPharmaceutical, has initiated patient recruitment for a Phase...

Company Drug

CanSino Biologics Enrolls First Patient in Phase I Trial of Innovative Polio Vaccine

Fineline Cube Jan 16, 2024

CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of...

Company Deals

Novartis Acquires Calypso Biotech for USD 250 Million to Bolster IL-15 Pipeline

Fineline Cube Jan 16, 2024

Novartis (NYSE: NVS) has finalized an agreement to acquire Netherlands-based Calypso Biotech, a 2013 spinout...

Company Deals

Cytokinetics Attracts Big Pharma Interest Amid Aficamten’s Phase III Success

Fineline Cube Jan 16, 2024

Cytokinetics (NASDAQ: CYTK), a specialist in cardiovascular diseases, is reportedly attracting interest from multiple Big...

Company Drug

RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer

Fineline Cube Jan 16, 2024

China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...

Company Drug

CSPC Pharmaceutical Secures FDA Approval for Clinical Study of JMT106 in GPC3-Positive Tumors

Fineline Cube Jan 16, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received approval from the US FDA to...

Company Deals

BioNTech Acquires Pre-Clinical Asset and ADC Technology from Portuguese Biotech CellmAbs

Fineline Cube Jan 15, 2024

Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC)...

Company Deals

NVIDIA Expands Healthcare Reach with Amgen’s deCode Partnership at JP Morgan Conference

Fineline Cube Jan 15, 2024

At the recent JP Morgan Healthcare Conference, US chip giant NVIDIA (NASDAQ: NVDA) announced a...

Company Deals

Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis

Fineline Cube Jan 15, 2024

Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...

Company Drug

MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment

Fineline Cube Jan 15, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...

Company Deals

Boai NKY Medical Holdings Partners with HuaDao Biopharma for CAR-T Therapy Incubator

Fineline Cube Jan 15, 2024

Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic...

Policy / Regulatory

China’s NHSA Unveils Measures to Secure Volume-Based Procurement Supply

Fineline Cube Jan 15, 2024

The National Healthcare Security Administration (NHSA) has issued a notification outlining key measures to ensure...

Company Drug

BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan

Fineline Cube Jan 15, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy...

Posts pagination

1 … 460 461 462 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.